Clinical Trials

1,080 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

186 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT05952453 2026-03-11

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

20 enrolled

Ovarian Neoplasms

NCT07042802 2026-03-06

A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer

Phase 1/2 Recruiting

110 enrolled

Phase EARLY_PHASE1 Recruiting

Ovarian Neoplasms

NCT05415709 2026-02-11

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

45 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05636111 2026-01-22

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Phase 1 Recruiting

34 enrolled

Ovarian Neoplasms

NCT06161025 2026-01-12

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

860 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06964009 2026-01-08

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Phase 1 Recruiting

30 enrolled

Ovarian Neoplasms

NCT06855069 2025-12-17

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

468 enrolled

Ovarian Neoplasms

NCT06476184 2025-12-05

SALVOVAR

250 enrolled

Ovarian Neoplasms

NCT06840002 2025-09-30

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

Phase 1/2 Recruiting

150 enrolled

Ovarian Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

970 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06492070 2025-08-27

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

70 enrolled

BreastGastrointestinalGynecologicThoracic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vulvar Neoplasms

NCT04778839 2025-08-06

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Phase 1 Recruiting

98 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms

NCT07022535 2025-07-02

PRESELECT-0

18 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07023484 2025-07-02

Preselect-1

126 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04055649 2025-06-18

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

62 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06023862 2025-06-15

DOVE

198 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06292286 2025-06-11

SCENIC

Phase NA Recruiting

18 enrolled

Ovarian Neoplasms

NCT06828354 2025-03-24

A Study of SHR-A1811 in Subjects With Ovarian Cancer

300 enrolled

Ovarian Neoplasms

NCT06735326 2024-12-16

Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

105 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06437353 2024-11-27

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

74 enrolled

Ovarian Neoplasms

NCT04921527 2024-10-18

CHIPRO

454 enrolled

Ovarian Neoplasms, Recurrence

NCT03287271 2024-08-12

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Phase 1/2 Recruiting

90 enrolled

Neoplasms, Ovarian Neoplasms

NCT06394492 2024-08-09

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

440 enrolled

Ovarian Neoplasms

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

40 enrolled

Ovarian Neoplasms, Recurrence

NCT02429687 2023-04-25

MOGCT-01

129 enrolled

Ovarian Germ Cell Cancer, Ovarian Neoplasms

NCT02429700 2023-04-25

SCST-01

132 enrolled